Gossamer Bio, Inc. (GOSS)
Gossamer Bio, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in San Diego, CA, US. The stock last traded at $0.18, down 1.54% on the session, giving a market capitalisation of $87.5M. On trailing twelve-month figures it carries a trailing P/E of -0.23, a net margin of -324.8%. Its beta of 2.04 implies it has historically moved more than the broad market.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Gossamer Bio, Inc. is most often compared with the following Healthcare names: